SCHEMBL6113147

SCHEMBL6113147

CC(C)=CC(O)C[C@H](C)c1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.50
ACHE P22303 2/20 0.42
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
TRPA1 O75762 4/20 0.34
GRIA4 P48058 1/20 0.34
SRC P12931 1/20 0.33
ALOX5 P09917 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CHRNA7 P36544 1/20 0.31
MIF P14174 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
CA7 P43166 1/20 0.31
AKR1C3 P42330 1/20 0.31
AKR1C2 P52895 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160777 1.00 STAT3 (0.50) STAT3ACHEESR1ESR2TRPA1
SCHEMBL6113339 1.00 STAT3 (0.50) STAT3ACHEESR1ESR2TRPA1
SCHEMBL16352686 0.88 STAT3 (0.45) STAT3ACHEESR1ESR2TRPA1
SCHEMBL18545374 0.84 STAT3 (0.51) STAT3ACHEESR1ESR2TRPA1
SCHEMBL14731828 0.81 STAT3 (0.49) STAT3ACHEESR1ESR2TRPA1
SCHEMBL16363921 0.81 STAT3 (0.49) STAT3ACHEESR1ESR2TRPA1
SCHEMBL14731702 0.81 STAT3 (0.49) STAT3ACHEESR1ESR2TRPA1
SCHEMBL19361091 0.78 STAT3 (0.46) STAT3ACHEESR1ESR2TRPA1
SCHEMBL27778249 0.77 ACHE (0.50) STAT3ACHEESR1ESR2TRPA1
SCHEMBL6113156 0.74 STAT3 (0.43) STAT3ACHEESR1ESR2GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049723-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. 2017-02-23 US claimed
US-20160137588-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. 2016-05-19 US claimed
EP-2458983-B1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS INC (US) 2015-07-08 EP claimed
US-20140080916-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. (US) 2014-03-20 US claimed
EP-2670402-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE Cognition Therapeutics, Inc. (US) 2013-12-11 EP claimed
WO-2012106426-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. (US) 2012-08-09 WO claimed
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-05-24 US claimed
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-9815770-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2017-11-14 US disclosed
US-9815770-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2017-11-14 US disclosed
US-9815770-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2017-11-14 US disclosed
EP-2670402-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE Cognition Therapeutics, Inc. (US) 2013-12-11 EP disclosed
WO-2013029060-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2013-02-28 WO disclosed
WO-2012106426-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. (US) 2012-08-09 WO disclosed
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
WO-2011014880-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 STAT3 4728/4885ACHE 398/4885ESR1 3137/4885
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT STAT3 3872/4885ACHE 2/4885ESR1 4324/4885
US-20170049723-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE APP, MAPT, PSEN1 STAT3 284/4885ACHE 6/4885ESR1 4310/4885
US-20160137588-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT STAT3 3872/4885ACHE 2/4885ESR1 4324/4885
US-20140080916-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE APP, MAPT, PSEN1 STAT3 284/4885ACHE 6/4885ESR1 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.